Electrophysiology of dopamine in normal and denervated striatal neurons

Paolo Calabresi, Diego Centonze, Giorgio Bernardi

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Parkinson's disease (PD) symptoms originate from the loss of the dopaminergic control of neuronal activity in the striatum. Permanent loss of dopaminergic terminals in the striatum results in an abnormal activity of striatal neurons. The therapeutic treatment width exogenous dopamine, therefore, temporarily restores a balanced synaptic excitation of striatal neurons, counteracting pre- and postsynaptically the excessive glutamate release caused by the degeneration of nigrostriatal dopaminergic fibers. However, chronic treatment is associated with adverse effects that might reflect nonphysiological dopamine replacement. Basic studies on experimental animal models of PD are of crucial importance for the development of therapeutic agents able to provide relief to individuals with PD, without the adverse effects associated with currently available drugs.

Original languageEnglish
JournalTrends in Neurosciences
Volume23
Issue number10 SUPPL.
Publication statusPublished - 2000

Fingerprint

Corpus Striatum
Electrophysiology
Parkinson Disease
Dopamine
Neurons
Glutamic Acid
Animal Models
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Electrophysiology of dopamine in normal and denervated striatal neurons. / Calabresi, Paolo; Centonze, Diego; Bernardi, Giorgio.

In: Trends in Neurosciences, Vol. 23, No. 10 SUPPL., 2000.

Research output: Contribution to journalArticle

@article{6520680f449548b1b56aa251526d9b30,
title = "Electrophysiology of dopamine in normal and denervated striatal neurons",
abstract = "Parkinson's disease (PD) symptoms originate from the loss of the dopaminergic control of neuronal activity in the striatum. Permanent loss of dopaminergic terminals in the striatum results in an abnormal activity of striatal neurons. The therapeutic treatment width exogenous dopamine, therefore, temporarily restores a balanced synaptic excitation of striatal neurons, counteracting pre- and postsynaptically the excessive glutamate release caused by the degeneration of nigrostriatal dopaminergic fibers. However, chronic treatment is associated with adverse effects that might reflect nonphysiological dopamine replacement. Basic studies on experimental animal models of PD are of crucial importance for the development of therapeutic agents able to provide relief to individuals with PD, without the adverse effects associated with currently available drugs.",
author = "Paolo Calabresi and Diego Centonze and Giorgio Bernardi",
year = "2000",
language = "English",
volume = "23",
journal = "Trends in Neurosciences",
issn = "0378-5912",
publisher = "Elsevier Limited",
number = "10 SUPPL.",

}

TY - JOUR

T1 - Electrophysiology of dopamine in normal and denervated striatal neurons

AU - Calabresi, Paolo

AU - Centonze, Diego

AU - Bernardi, Giorgio

PY - 2000

Y1 - 2000

N2 - Parkinson's disease (PD) symptoms originate from the loss of the dopaminergic control of neuronal activity in the striatum. Permanent loss of dopaminergic terminals in the striatum results in an abnormal activity of striatal neurons. The therapeutic treatment width exogenous dopamine, therefore, temporarily restores a balanced synaptic excitation of striatal neurons, counteracting pre- and postsynaptically the excessive glutamate release caused by the degeneration of nigrostriatal dopaminergic fibers. However, chronic treatment is associated with adverse effects that might reflect nonphysiological dopamine replacement. Basic studies on experimental animal models of PD are of crucial importance for the development of therapeutic agents able to provide relief to individuals with PD, without the adverse effects associated with currently available drugs.

AB - Parkinson's disease (PD) symptoms originate from the loss of the dopaminergic control of neuronal activity in the striatum. Permanent loss of dopaminergic terminals in the striatum results in an abnormal activity of striatal neurons. The therapeutic treatment width exogenous dopamine, therefore, temporarily restores a balanced synaptic excitation of striatal neurons, counteracting pre- and postsynaptically the excessive glutamate release caused by the degeneration of nigrostriatal dopaminergic fibers. However, chronic treatment is associated with adverse effects that might reflect nonphysiological dopamine replacement. Basic studies on experimental animal models of PD are of crucial importance for the development of therapeutic agents able to provide relief to individuals with PD, without the adverse effects associated with currently available drugs.

UR - http://www.scopus.com/inward/record.url?scp=0033710029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033710029&partnerID=8YFLogxK

M3 - Article

C2 - 11052221

AN - SCOPUS:0033710029

VL - 23

JO - Trends in Neurosciences

JF - Trends in Neurosciences

SN - 0378-5912

IS - 10 SUPPL.

ER -